Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Monitoraggio Mensile del Plasma NfL nella Sclerosi Multipla Recidivante-Remittente Trattata per Rilevare l'Attività Infraclinica Persistente della Malattia (MoMo-NfL)

2 novembre 2026 aggiornato da: Centre Hospitalier Universitaire de Nīmes

Monitoraggio mensile del NfL plasmatico nella SMRR trattata per rilevare un'attività di malattia infraclinica persistente

Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2/FLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response. However, some studies have suggested the deposition of gadolinium-based contrast agents in the basal ganglia and dentate nucleus of patients who underwent serial MRI acquisitions. Although significant clinical consequences of these deposits have not been demonstrated, further studies are required to better understand the potential long-term biological and clinical effects of gadolinium administration. To circumvent this potential risk, several recommendations suggested avoiding unnecessary use of gadolinium for follow-up scans. New sequences are also developed to replace gadolinium injection for the detection of active lesions. Moreover, MRI remains costly and time-consuming. In addition, systematic yearly MRI monitoring is not adapted to detect silent active lesions. This can delay identification of treatment failure and increase the risk of relapses and disability worsening, especially in the context of escalation therapy.

Therefore, biological markers could allow more frequent analysis of disease activity and detect treatment failure earlier than classical clinical and MRI monitoring. Their use would greatly help clinicians to switch for high efficacy treatments (HET) and avoid potential relapses.

Measurement of a structural axonal protein, neurofilament, in serum or plasma has shown promise as a marker of neuroaxonal injury and a measure of treatment response. In MS, cerebrospinal fluid (CSF) neurofilament-light chain (NfL) is also increased and is positively associated with MRI lesion load and disability scores and is a marker of treatment response.

WThe study authors hypothesize that monthly plasma neurofilament-light chain (pNfL) monitoring can sensitively highlight subclinical (radiological disease activity) RDA by performing early MRI scans to confirm EDA and lead to timely treatment escalation.

The main objective of this study is to compare the time to EDA in both arms (monthly pNfL monitoring vs. standard care with regular MRI scans), in patients with EDA.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

84

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Montpellier, Francia, 34295
        • Reclutamento
        • CHU de Montpellier - Hôpital Guy de Chauliac
        • Contatto:
      • Nantes, Francia, 44000
        • Non ancora reclutamento
        • CHU de Nantes
        • Contatto:
      • Nice, Francia
      • Nîmes, Francia
        • Reclutamento
        • CHU de Nîmes
        • Contatto:
      • Paris, Francia, 75013
        • Reclutamento
        • AP-HP, Hôpital de la Pitié Salpêtrière
        • Contatto:
      • Rennes, Francia
        • Non ancora reclutamento
        • CHU de Rennes
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patient with RRMS according to 2024 McDonald's criteria.
  • Less than 10 years from disease onset.
  • Active RRMS (EDA) observed during the last 24 months: relapse and/or NELs and/or CELs as compared to a previous MRI performed within 24 months (± 3 months).
  • Current MET (IFN, GA, TE, fumarates) for less than 24 months.
  • Standard MRI follow-up scan performed less than 90 days before inclusion.
  • Clinically stable disease for at least 30 days.
  • Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.
  • For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.
  • Patients able to adhere to the study visit schedule.
  • Patient must have signed and given the consent.
  • Patient affiliated or beneficiary of a health insurance plan.

Exclusion Criteria:

  • Pregnant or breastfeeding woman.
  • Patient unable to perform brain and/or spinal cord MRI scans.
  • Patient not willing to perform monthly blood punctures.
  • Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).
  • Patient with a relapse within 6 months before inclusion.
  • Patient with CELs within 3 months before inclusion.
  • Patient with progressive MS.
  • Patient unable to sign the consent.
  • It is impossible to correctly inform the patient.
  • Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1/2) of the experimental drug.
  • Patient under judicial protection, or is an adult under guardianship.
  • Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Cura standard
Sperimentale: gruppo di monitoraggio pNfL

Monthly pNfL monitoring from blood samples. In case of >50% pNfL increase as compared to the mean of the 2 previous measures, an unscheduled visit with brain and spinal cord MRI will be scheduled

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to evidence of disease activity between groups
Lasso di tempo: week 48

As assessed by new relapse and/or occurrence of NELs and/or CELs on a follow-up MRI scan

week 48
Time to evidence of disease activity between groups
Lasso di tempo: week 96

As assessed by new relapse and/or occurrence of NELs and/or CELs on a follow-up MRI scan

week 96

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of CELs between groups
Lasso di tempo: week 48

percent of active (contrast-enhancing) lesion

week 48
Proportion of CELs between groups
Lasso di tempo: week 96

percent of active (contrast-enhancing) lesion

week 96
Rate of clinical relapses between groups
Lasso di tempo: week 48

percentage patients experiencing relapse

week 48
Rate of clinical relapses between groups
Lasso di tempo: week 96

percentage patients experiencing relapse

week 96
Time to switch to high efficacy treatments
Lasso di tempo: week 48

Days

week 48
Time to switch to high efficacy treatments
Lasso di tempo: week 96

Days

week 96
Proportion of patients switching to high efficacy treatments between groups
Lasso di tempo: week 48

Percentage

week 48
Proportion of patients switching to high efficacy treatments between groups
Lasso di tempo: week 96

Percentage

week 96
Change in pNfL levels in patients experiencing relapse with active MRI in experimental group
Lasso di tempo: Upon experiencing relapse (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing relapse (maximum week 96)
Change in pNfL levels in patients experiencing acute clinical event in experimental group
Lasso di tempo: Upon experiencing an acute clinical event (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing an acute clinical event (maximum week 96)
Change in pNfL levels in patients experiencing radiological disease activity without clinical symptoms in experimental group
Lasso di tempo: Upon experiencing radiological disease activity (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing radiological disease activity (maximum week 96)
Change in pNfL levels in patients switching to high efficacy treatments
Lasso di tempo: Upon evidence of disease activity (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon evidence of disease activity (maximum week 96)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To estimate the best threshold of pNfL increase (last measure as compared to the mean of 2 previous measures) with best accuracy to detect evidence of disease activity
Lasso di tempo: week 96

pNfL levels in pg/mL

week 96
Time to evidence of disease activity using optimized threshold in experimental group
Lasso di tempo: week 96

Months

week 96
Correlation between basal pNfL fluctuations in patients with no evidence of disease activity and brain health questionnaire score
Lasso di tempo: week 96

Brain-Q

week 96
Description of adverse events
Lasso di tempo: week 96

Descriptive

week 96
Level of disability
Lasso di tempo: Baseline (Day 0)

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

Baseline (Day 0)
Level of disability
Lasso di tempo: Week 48

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

Week 48
Level of disability
Lasso di tempo: week 96

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

week 96
Information processing speed impairment
Lasso di tempo: Baseline (Day 0)

CSCT (Computerized Speed Cognitive Test): score and standard deviation

Baseline (Day 0)
Information processing speed impairment
Lasso di tempo: week 48

CSCT (Computerized Speed Cognitive Test): score and standard deviation

week 48
Information processing speed impairment
Lasso di tempo: week 96

CSCT (Computerized Speed Cognitive Test): score and standard deviation

week 96
Manual dexterity
Lasso di tempo: Baseline (Day 0)

NHPT (Nine Hole Peg Test): time (seconds)

Baseline (Day 0)
Manual dexterity
Lasso di tempo: week 48

NHPT (Nine Hole Peg Test): time (seconds)

week 48
Manual dexterity
Lasso di tempo: week 96

NHPT (Nine Hole Peg Test): time (seconds)

week 96
Walking function
Lasso di tempo: Baseline (Day 0)

T25FW (Timed 25-Foot Walk); time (seconds)

Baseline (Day 0)
Walking function
Lasso di tempo: week 48

T25FW (Timed 25-Foot Walk); time (seconds)

week 48
Walking function
Lasso di tempo: week 96

T25FW (Timed 25-Foot Walk); time (seconds)

week 96
Patient-reported change in status
Lasso di tempo: Baseline (Day 0)

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

Baseline (Day 0)
Patient-reported change in status
Lasso di tempo: Week 48

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

Week 48
Patient-reported change in status
Lasso di tempo: week 96

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

week 96
Patient-reported quality of life
Lasso di tempo: Baseline (Day 0)

EQ-5D-5L score (0-100)

Baseline (Day 0)
Patient-reported quality of life
Lasso di tempo: week 48

EQ-5D-5L score (0-100)

week 48
Patient-reported quality of life
Lasso di tempo: week 96

EQ-5D-5L score (0-100)

week 96

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Eric Thouvenot, Centre Hospitalier Universitaire de Nīmes

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 dicembre 2025

Completamento primario (Stimato)

1 dicembre 2030

Completamento dello studio (Stimato)

1 dicembre 2030

Date di iscrizione allo studio

Primo inviato

5 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

5 dicembre 2025

Primo Inserito (Effettivo)

18 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • FINEX/2025/ET-01

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .